| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 3, 2026Next | Q2 2027 | — | 10.81 | 111 B |
Sep 1, 2026
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Aug 29, 2026
McKesson Corporation (NYSE:MCK) has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-growth businesses. Precision Medicine provides clinical research, laboratory testing, and commercialization services to biotechnology and pharmaceutical companies developing and launching new medicines. McKesson plans to integrate the company into its […]
Aug 28, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000927653/000092765326000247/mck-20260825.htm
Aug 27, 2026
McKesson (NYSE:MCK) announced an agreement to acquire Precision Medicine Group to expand its oncology and clinical research services. The deal is aimed at deepening McKesson's role in personalized medicine and specialty care, particularly in oncology and biopharma clinical trial support. The acquisition is expected to reshape McKesson's service mix across oncology practices, biopharma partners and clinical research organizations. For readers looking beyond McKesson to other potential...
McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 3.54% on an annualized basis producing an average annual return of 17.04%. Currently, McKesson has a market capitalization of $103.82 billion.
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Aug 26, 2026
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services.
Aug 25, 2026
The drug distributor will fold the clinical research and biopharma commercialization firm into its oncology unit once the deal closes
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
McKesson (MCK) has agreed to acquire Precision Medicine in a transaction worth roughly $2.25 billion
McKesson Corporation (NYSE:MCK) on Tuesday announced an agreement to acquire Precision Medicine Group.The deal provides McKesson with an opportunity to expand its clinical research and commercialization services.McKesson will acquire Precision Medicine Group for approximately $2.25 billion.Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment, its second-largest segment with first-quarter sales of $14.2 billion.McKesson
IRVING, Texas, August 25, 2026--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC ("Precision Medicine Group"), a global provider of clinical research and biopharma commercialization services.
Aug 24, 2026
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
McKesson has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.
Aug 21, 2026
McKesson stock has delivered a very strong 336.0% return over the past five years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below their estimated worth. Over 5 years, McKesson has returned 336.0%, which puts recent share price moves in the context of a long and very strong run. Expectations for McKesson's ability to keep converting revenue into reliable cash flows can support the...
Aug 20, 2026
McKesson (MCK) is in focus after its technology leadership team joined the 17th Annual Atlanta C-Level Technology Leadership Summit, highlighting how its healthcare technology services fit alongside recent quarterly results and the current stock performance. See our latest analysis for McKesson. At a share price of $853.71, McKesson has eased slightly in the very short term, with a 1-day share price return that declined 1.79% and a 7-day share price return that declined 2.85%. However, its...
Aug 19, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare providers & services stocks fared in Q2, starting with McKesson (NYSE:MCK).
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.
RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.
